Last year was an excellent year for the major market indices, with the S&P 500 returning nearly 27%. The most popular benchmark beat the Dow Jones Industrial Average and the Nasdaq Composite by the widest margins since 1997.
However, rising government bond yields and unabating inflation have been fostering significant market volatility. Investors are concerned because the Federal Reserve has said that it might be forced to implement interest rate hikes earlier than expected to keep inflation in check.
Given this backdrop, investors looking to sidestep market volatility could add high-yield S&P 500 dividend stocks AbbVie Inc. (ABBV – Get Rating), Merck & Co., Inc. (MRK – Get Rating), and GlaxoSmithKline plc (GSK – Get Rating) to their portfolios now to ensure a steady stream of income.
AbbVie Inc. (ABBV – Get Rating)
Biopharmaceutical company ABBV in North Chicago, Ill., researches, develops, manufactures, commercializes, and sells medicines and therapies. The company is present in various therapeutic categories, including immunology, oncology, aesthetic, neuroscience, and women’s health products.
On Sept. 28, 2021, ABBV announced that the U.S. Food and Drug Administration had approved QULIPTA for the preventive treatment of episodic migraine in adults. It is the first and only oral calcitonin gene-related peptide receptor antagonist developed explicitly for the prophylactic treatment of migraine. The therapy is expected to increase its sales worldwide due to its high efficacy, safety, and tolerability.
Over the… Continue reading on StockNews.com